Introduction:Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of recurrence. Currently recommended treatments are not efficient for prevention...
Background: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy.
Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase III vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to $ 380 million, including $ 270 million in an upfront payment and up to $ 110 million in future conditional milestone payments
Emergent BioSolutions Inc. announced that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines...
There is significant diversity in the utilization of antibiotics for neonates undergoing surgical procedures. Our institution standardized antibiotic administration for surgical neonates, in which no empiric antibiotics...
The objective of this review was to describe the epidemiology of sleep apnea in chronic kidney disease, understand the pathophysiological mechanisms by which OSA can lead to progression of chronic kidney disease, and consider the role of treatment with CPAP in this regard.
Introduction: The interleukin (IL)-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis. Risankizumab can selectively inhibit IL-23p19 subunit and for the treatment of psoriasis.
Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysregulated inflammation. Therapeutic innovations such as nebulized antimicrobial therapy targeting specific pathogens have resulted in...
This updated guideline provides a current review of the literature on interventions to control CDI in adult populations in acute healthcare settings and derives specific infection control recommendations.
ViATIM is indicated for simultaneous active immunisation against typhoid fever and hepatitis A virus infection in subjects from 16 years of age. ViATIM should be given in accordance with official recommendations.